• Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness
• Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medication
• Reasons advanced for the suboptimal adherence include lack of awareness or treatment, increased number of prescribed medications, and major adverse effects of the prescribed drugs
• Lexaria has so far shown that its DehydraTECH-CBD is not only effective but also well tolerated and is planning to undertake registered clinical trials in pursuit of the FDA’s approval of the drug candidate

A recent research article published in the Journal of the American Heart Association (“AHA”) unearths data that suggests poorly controlled hypertension among both men and women (https://ibn.fm/oy2TN), a problem global innovator Lexaria Bioscience (NASDAQ: LEXX) is keen on solving. The researchers, who sought to describe gender-differential disease patterns and results of more than 20.6 million emergency department encounters in the United States from 2016 to 2018, made several observations. Firstly, most ED cardiovascular (“CVD”) visits in the sample were due to hypertensive diseases. Secondly, essential hypertension, which is high blood pressure not resulting from other maladies, was the most common CVD diagnosis in women and second most common in men (https://ibn.fm/2b9jQ). Moreover, the article notes, “Attendances for essential hypertension were more common in women, which may reflect higher rate of preexisting hypertension in women (76.6% vs. 74.4%). These findings may also reflect poorer control of hypertension or poorer access to primary care in women… Further supporting these suppositions, in our sample, although men were less likely to present to the ED with essential hypertension, they were slightly more likely to present with long-term consequences of hypertension-related end-organ damage (hypertensive heart or kidney disease) and were more likely to die following such presentations, suggesting longer duration of exposure to poorly controlled hypertension than women.” This recent study is one of the latest in a series of research works on uncontrolled hypertension that date back to the 20th century. In a scholarly article published in 2005 in the AHA Journal, for example, researchers observed a high prevalence of uncontrolled hypertension that suggested a significant number of CVD events could be prevented by improved blood pressure control. “The benefits of pharmacological treatment for [hypertensive] patients are well established. Meta-analysis of randomized placebo-controlled trials indicate that antihypertensive therapy reduces the risk of stroke by approximately 30%, coronary heart disease by 10-20%, congestive heart failure by 40-50%, and total mortality by 10%,” the 2005 research article continues (https://ibn.fm/9WAMD). Several other studies have put forth reasons that are thought to cause suboptimal adherence, leading to poor control. These reasons include the lack of awareness or treatment, an increased number of antihypertensive drugs, and major adverse effects, just to mention a few (https://ibn.fm/46bPk). As this happens, hypertension remains the leading cause of noncommunicable disease deaths globally, raising concerns that have caught the attention of Lexaria, a company developing a potential hypertension treatment with little to no side effects. The treatment is created by processing cannabidiol (“CBD”) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (“APIs”). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood by as much as 317% but also reduces blood pressure and arterial stiffness. To put these findings into a more comprehensive context, the company’s 24-person human clinical study, christened HYPER-H21-1, evidenced a rapid and sustained drop in blood pressure. The second study, HYPER-H21-2, a 16-person HCS, showed up to a 23% reduction in overnight blood pressure as well as reduced arterial stiffness, while the third study, HYPER-H21-3, evidenced attenuated pulmonary artery systolic pressure. What the three studies had in common was that no serious adverse events were reported, suggesting that DehydraTECH-CBD is well tolerated (https://ibn.fm/BZWuX). To further confirm this fact, Lexaria is working toward a planned Phase I(b) trial, expected to commence following the filing of an Investigational New Drug (“IND”) application and the fulfillment of other regulatory requirements. According to the company, the IND-enabling program is currently underway and is expected to be completed later this year or early next year (https://ibn.fm/dOnXv). Lexaria hopes to prove, through registered clinical trials, that its DehydraTECH-CBD formulation has an acceptable safety and tolerability profile and that it is effective against hypertension. The proof could potentially influence the registration of DehydraTECH-CBD as the second FDA-approved CBD drug, offering a reprieve to millions of hypertension patients who do not have their condition under control because they receive numerous antihypertensive drugs or are unwilling to suffer through these medications’ adverse side effects. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Colombia and the United States have both recently exhibited new openness to the possibility of decriminalizing adult recreational cannabis use through legislative change
• Cannabis supplier Flora Growth cultivates its product at a key Colombian farm and provides it to international markets, and may see additional opportunities arise as cannabis policies advance in the two countries
• Flora Growth recently announced completion of its first shipments of high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate supplied to its market in the United States
• The company also recently reported a 604 percent YOY increase in revenues during the H1 reporting period, with a 547 percent gross profit increase during that period

Cannabis may be approaching a new watershed moment as Colombia pushes for national legalization of adult-use marijuana and the United States’ government undertakes long-anticipated discussion of whether to change the drug’s classification. The nearly unanimous approval of legislation to legalize and regulate adult-use cannabis by an initial committee reviewing bills in Colombia’s legislature, coupled with the president’s criticisms of decades-long prohibitionist policies and regulatory advances made by his predecessor, position the fertile country with a storied history on the front lines of the global war on drugs to become a major legal producer of cannabis and its derivatives (https://ibn.fm/nuBv7). In the United States, the President recently issued executive pardons to criminals convicted of marijuana possession in federal cases and asked federal health and law enforcement agencies to take a fresh look at the possibility of ending marijuana’s classification as an illicit substance, creating energy for cannabis stocks in the country (https://ibn.fm/2CkcE). International cannabis company Flora Growth (NASDAQ: FLGC) is headquartered in Fort Lauderdale, Florida but operates its cultivation from a 100-hectare (about 247-acre) licensed farming facility in northern Colombia where it develops cannabis products and then ships them into international markets or to its GMP-certified facility in the nation’s capital for transformation into consumer ready goods. The company’s NASDAQ listing precludes it from participating in the U.S. domestic market for adult-use cannabis at present, where marijuana has enjoyed some approval on a state-by-state basis despite the federal prohibitions. But the continually developing approach to recreational cannabis use in Colombia and the United States portends possible new opportunities for the company beyond its current low-cost operation supplying THC and CBD flower and derivatives to international markets and the CBD it provides to its own product supply chain. “We are proud to help increase access to safe, legal CBD and THC to consumers all over the globe,” Flora Growth Chairman and CEO Luis Merchan stated last month after the company announced completion of its first exports to of high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate supplied to its market in the United States (https://ibn.fm/bFVa2). Investors have taken a wary approach to cannabis stocks amid ongoing global economic turmoil continuing beyond the immediate impact of the COVID pandemic. But financial data reported by Flora Growth indicates the company has reason for optimism that its strategic advances are taking it in the right direction. Flora’s most recent revenue report states that revenues increased 604 percent increase YOY during the H1 period and 117 percent of the previous half-year report (https://ibn.fm/SK2gD). “Our gross profit increased 547 percent over that same period last year and we expect our revenues for the full year to grow between 300 and 400 percent for … 2022,” Merchan said as part of the management’s analysis of the results. “Despite (COVID-related challenges and economic uncertainty), Flora business units continue to improve their performance.” For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Net-Zero initiatives critical to combatting climate change according to global policymakers, worldwide coalition formed to cut greenhouse gas emissions to as close to zero as possible by 2050
• Transition from fossil hydrocarbon-based energy systems requires massive reconfiguration of energy systems
• GeoSolar’s SmartGreen(TM) Home system provides complete total-home energy “makeover” comprising solar panels, geothermal ground loops, LED lighting, upgraded insulation, energy-efficient windows
• GeoSolar conducting Regulation A+ capital raise with minimum $300 investment

Transitioning to “Net-Zero” – a concept first promoted at the United Nations Climate Change Conference (COP21) – is critical to combatting the effects of climate change, according to global policymakers (https://ibn.fm/dMgSK). Since then, a coalition representing major cities, businesses, investors, and educational institutions has formed to promote initiatives aiming to achieve net-zero carbon emissions by 2050. GeoSolar Technologies (“GST”) is a Colorado-based climate technology company dedicated to Net-Zero initiatives by helping residents and businesses reduce carbon emissions and achieve energy independence. The company’s SmartGreen(TM) Home systems harness the power of the sun and earth to heat and cool buildings, charge electric vehicles, and run electric appliances while purifying the air and maximizing energy efficiency. “Much technology has to be developed, not just on emissions, but on sequestration and all the other technologies we’re talking about to get to zero carbon,” said John Anderson, President of The National Academies of Sciences, Engineering, and Medicine in a recent interview (https://ibn.fm/RdSff). “The transition from our current fossil hydrocarbon-based energy system to a net-zero carbon future is going to require a massive reconfiguration of our entire global energy system.” With an eye on global Net-Zero goals, GeoSolar ’s technology empowers building owners to act locally by leveraging a mix of renewable energy sources. The company’s patent pending SmartGreen(TM) Home system is a total building energy “makeover” that comprises solar panels and geothermal ground loops to maintain temperature and power household appliances and electric vehicles. “The first priority is to deploy known technologies that have been developed over the past 20 or 30 years to address easy-to-decarbonize processes,” continued Anderson. “So, what’s easy to decarbonize? HVAC in homes, local transportation around cities, electric vehicles, household appliances, and so on, because we have various solutions already available.” SmartGreen(TM) builds upon those existing solutions and takes them further with additional measures that include tightening the building envelope and upgrading insulation, windows, and lighting systems. With options to build systems into new construction or existing buildings, SmartGreen(TM) helps property owners cut CO2 emissions by up to 8 tons per year while reducing or even eliminating energy bills (https://ibn.fm/TeYJY). GeoSolar aims to take SmartGreen(TM) mainstream by marketing the system to 120 million homes across the United States. The company is currently conducting a Regulation A+ capital raise that allows the public to invest in a carbon-free future for as little as $300 (https://ibn.fm/ZUaLw). For more information on GeoSolar’s Regulation A+ capital raise, please visit www.manhattanstreetcapital.com/geosolar-technologies-inc. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Odyssey Health is a medical company developing unique, life-saving products that address unmet clinical needs such as concussion, which does not have an FDA-approved therapeutic
• The company has developed PRV-002, a neurosteroid for the treatment of concussion, and an intranasal delivery device that delivers the drug into the upper chamber of the nasal cavity for onward travel into the brain
• Odyssey’s just concluded Phase I clinical trial shows that PRV-002 is safe and well tolerated
• The findings from the study are likely to benefit the military as well as the NFL, given military personnel and players frequently suffer concussions

In 2002, NFL Pro Hall of Famer and former center Michael Lewis Webster became the first ex-NFL player to be diagnosed through autopsy with chronic traumatic encephalopathy (“CTE”), a degenerative brain disorder believed to be caused by repeated concussions (https://ibn.fm/ZxgeE). Since then, doctors, the NFL in general, and medical companies like Odyssey Health (OTC: ODYY) have learned a lot about concussions and CTE. On its part, the NFL has progressively implemented a raft of player safety policies aimed at protecting players. Despite the spate of safety policies, which include fines and suspensions to players, football remains a dangerous sport that sees players with massive physiques collide with one another. It is no question that this physicality can cause damage to the brain and body, and a recent incident, which has elicited widespread criticism and uproar from fans and coaches alike, demonstrates the danger posed. In the last week of September – week three, the football community watched in horror as Dolphins Quarterback Tua Tagovoiloa sustained yet another concussion just a week after he had been taken out of a game and probed for a possible concussion, with criticism pouring as to why the Dolphins coaching staff had included him in the day’s playing roster in the first place. The criticism and concern around concussions are valid. As of 2017, over 100 ex-NFL players had received postmortem diagnoses of CTE (https://ibn.fm/epRtP). In addition, scores of players have been forced into early retirement after they suffered a concussion (https://ibn.fm/V956u). In understanding the dangers, coaches like the New England Patriots’ Bill Belichick have learned the telltale signs of unwell players. Belichick has even had to take players out of games because he suspected they had sustained a concussion, sometimes going against medical staff who had cleared them to play (https://ibn.fm/wMvbj). But an intervention that could potentially improve the efficacy of the NFL’s concussion protocol and prevent the development of concussion symptoms by reducing brain swelling, inflammation, and oxidative stress as well as normalizing blood flow to the brain is in the works. The intervention being developed by Odyssey as a potential treatment for concussion is a novel non-naturally occurring neurosteroid by the name PRV-002 delivered through the company’s patent-pending breath-propelled intranasal drug delivery device. Odyssey believes the drug candidate could boost the chances of successful recovery for concussed patients by taking advantage of the drug-device combination’s ability to facilitate quick administration of PRV-002. A dry powder that does not require special handling or refrigeration, PRV-002 can sit on the sidelines of football games, allowing medical staff to administer it immediately if they suspect a player has sustained a concussion. According to Odyssey, the intranasal delivery device delivers the dry powder into the upper chamber of the nasal cavity without being swallowed or inhaled. The drug then travels along the cranial nerve toward the brain, where it crosses the blood-brain barrier within 5 minutes of administration and spreads throughout the brain within 30 minutes, reversing the effects of a concussion. The drug candidate was recently administered to healthy volunteers as part of a just-concluded Phase I clinical trial, which demonstrated that PRV-002 was safe and well tolerated (https://ibn.fm/JWh5R). Next, Odyssey is planning to undertake a Phase II study that will investigate PRV-002’s efficacy in concussed patients. The company will initially conduct its evaluations in select military training camps, where military personnel frequently sustain concussions during training. Eventually, however, Odyssey wishes to move into athletic models working in conjunction with the National Collegiate Athletic Association’s (“NCAA”) medical centers, possibly by 2023 (https://ibn.fm/e3bO7). The findings from the upcoming study are likely to benefit military personnel and NFL players who are highly vulnerable to concussions. According to the latest data from the Military Health System, for example, 377,425 members of the U.S. Armed Forces had suffered a concussion (also known as mild traumatic brain injury) between 2000 and the first quarter of this year (https://ibn.fm/G8zAp). On the other hand, NFL’s injury data shows that in each of the five years to 2019, the total number of concussions suffered during practice and gameplay was well above 200. And although the figures dropped in 2020 and 2021 due to COVID-19 and a change in the NFL season structure, respectively, over 170 concussions were reported in each of these seasons (https://ibn.fm/6sYAI). For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• The global electric vehicle fleet will rise to between 140-240mn cars by 2030, resulting in over 7TW of battery capacity
• The growth of the EV industry as well as the rise in renewable power sources has led to rising interest in vehicle-to-grid technology
• Vehicle-to-grid technology allows for an electric vehicle to engage in bidirectional charging, effectively allowing a vehicle to drive excess power back into the grid
• Through their revolutionary enhanced powertrain solution, Hillcrest Energy Technologies are seeking to pioneer the way towards efficient bidirectional charging

The global electric vehicle population is set to swell to between 140 and 240 million electric battery-powered vehicles by 2030; in effect, it means we will have at least 140 million energy storage devices on wheels with an aggregated storage capacity of 7TWh (terawatt hours) on the road over the course of the next decade (https://ibn.fm/QtuHz). To put that into perspective, a global electric vehicle fleet of 140 million vehicles would effectively be able to power the United States’ annual electricity consumption twice over on a single charge. By some estimates, it could lead electricity consumption to rise by as much as 38 percent within the U.S. by 2050, a phenomenon that has thrust the vehicle-to-grid technology sector into the global spotlight. Vehicle-to-grid technology enables energy to be pushed back to the power grid from the battery of an electric car; with electric vehicle-to-grid technology – also known as car-to-grid – a car battery can be charged and discharged based on different signals, such as energy production or consumption nearby. With the global vehicle-to-grid technology market size forecast to grow from a value of $1.77 billion in 2022 to approximately $17.43 billion by 2027, a CAGR of more than 48 percent over the period in question, Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean technology company developing transformative power conversion technologies has sought to introduce its proprietary solution into the mix. Hillcrest Energy Technologies has filed a patent for an enhanced powertrain solution, which offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefits of the enhanced powertrain solution are the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Global energy grids are increasingly turning towards renewable energy to achieve global decarbonisation and net-zero targets. However, a key issue affecting the deployment of renewable energy sources relates to the storage of energy. While fossil fuels can be seen as a form of energy storage, given they release energy as they are burned, wind and solar energy produce power during intermittent intervals, thus necessitating new ways in which to balance and store energy. While some sources of renewable energy are cheaper in terms of electricity generation costs than conventional fossil fuels, surveys carried out by EIA have revealed the costs of installing and operating large-scale battery storage systems in the United States have declined in recent years. In 2019, the average battery energy storage capital costs $589 per kilowatthour (“kWh”), while battery storage costs fell by 72% between 2015 and 2019, a 27% per year rate of decline. The lowering costs give facilities more space to store energy which increases the duration of battery systems while in use. The price decline in energy storage has expanded beyond batteries into other technologies like hydrogen, compressed air, etc (https://ibn.fm/DY5Fe). This phenomenon in turn has driven ever-increasing interest into vehicle-to-grid technology, with electric vehicle batteries being the most cost-efficient form of energy storage given that they require no additional investments in hardware. While an electric vehicle battery will absorb electricity until it is fully charged, the ability for a vehicle to engage in ‘bidirectional’ charging would effectively allow for the vehicle-to-grid charging device to absorb any excess electricity from the car battery and push it back to the grid, where it continues its journey to the nearest location where it’s needed. The International Energy Agency (“IEA”) has predicted that global renewable electricity capacity will rise by more than 60 percent from 2020 levels to over 4,800 GW – equivalent to the current total global power capacity of fossil fuels and nuclear combined (https://ibn.fm/ZouUI). In fact, renewables are set to account for almost 95 percent of the increase in global power capacity through 2026. With the combined production plus battery storage costs for renewable sources yet to reach parity with conventional fuel sources, electric vehicle batteries may hold the answer for the next step of the global journey towards Net Zero. With its soon-to-be-commercialized enhanced powertrain solution, Hillcrest Energy Technologies is ready for the next phase in the global energy revolution. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• Congressional Democrats and the White House administration succeeded in passing a law this year that provides sky’s-the-limit funding incentives to clean energy efforts
• While the law appears to be ensured a long and healthy life, there are still hurdles to its implementation in the form of difficulties keeping pace with infrastructure and navigating the funding eligibility process
• Louisiana-based Correlate Infrastructure Partners Inc. (CIPI) is a company focused on helping companies implement climate-friendly changes through effective upgrades in utilities usage and adoption of alternative energy infrastructure
• CIPI also helps clients identify funding opportunities and how to put them to use
• Under the new law, the government has no funding or budget cap for providing incentives to green energy adoption, removing a financial obstacle for companies on the fence over utilities transition

When the Inflation Reduction Act passed through Congress and obtained the president’s signature in August, it ushered in a new era of investment into addressing climate change with unprecedented support for renewable energy. The law established funding for affordable healthcare, prescription drug price reduction, taxation reform, and deficit reduction, but notably for energy concerns it provides financial incentives for electric vehicles and other zero-carbon electricity industries. Louisiana-based clean energy solutions innovator Correlate Infrastructure Partners (OTCQB: CIPI) applauded the law’s passage as al means to boost the company’s efforts to further energy use reform through proprietary analytics and advisement for companies seeking to reduce the carbon footprint of their buildings. CIPI’s experts help its clients navigate the often-turbulent channels of the financing infrastructure to obtain the monetary backing they may need to make needed climate-friendly improvements. Analysts at the investment bank Credit Suisse published a research note in September that observed the credits for renewable energy incentives are uncapped, meaning the law does not establish any limitation on how much the government may spend in regard to the incentives — a true boon to companies that may have been on the fence as far as transitioning their operations to more climate-friendly standards. The bank’s analysts assessed future risks to the law’s green energy provisions as low, because even though it passed along partisan lines without Republican support, the bank believes that Republicans won’t undo it even if they gain a majority in coming elections because any retractions would likely hurt their own voters more than voters in Democratic-majority states. “Republican-leaning states are likely to see the most investment, job, and economic benefits from the IRA,” the analysts’ report claims, as noted in a recent Atlantic editorial (https://ibn.fm/5u8Ec). Credit Suisse’s assessment argues that the United States is in a position to become the world’s leading energy provider, adding to its leading position as an oil and natural gas producer with clean electricity and hydrogen production at a remarkably low cost, even if China retains its prominence in terms of battery production. Correlate Infrastructure’s ability to help clients identify benefits to their financial sheets as well as the global climate may be particularly welcome if the country slides farther toward an economic recession. “Even if the United States slips into recession in the next year, … the IRA’s programs and incentives will keep flowing no matter the macro environment, which makes betting on clean energy one of the most certain economic trends of the next few years. Clean energy is now the safe, smart, government-backed bet for conservative investors,” the Atlantic article states. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• While a tough economic climate has hurt many businesses in recent years, Golden Matrix has amassed a streak of 16 consecutive profitable quarters
• The GMGI portfolio includes over 10,000 games and a turnkey system designed to promote user acquisition, engagement, retention, and monetization
• After buying 80% of RKings International, GMGI is preparing to expand the business from its roots in the U.K. and Ireland into the Latin American markets

The online gambling space is highly competitive, lending to most of the world’s biggest operators burning through tons of cash for marketing in a bid to try and attracts (and keep) customers. That’s cash that comes straight off the bottom line, explaining why many struggle to achieve profitability. That’s certainly not the case for Golden Matrix Group (NASDAQ: GMGI), which continues to experience revenue growth on its way to amassing an impressive streak of 16 straight profitable quarters. The Las Vegas-based upstart is a developer and licensor of highly modular, configurable, and scalable gaming platforms for its international customers designed to promote user acquisition, engagement, retention, and monetization. Golden Matrix white labels its industry-leading GM-AG System that can be custom built from 10,000+ game options for its roughly 650 clients serving about 6.8 million end users. While the coronavirus pandemic was a detriment to many businesses and industries forced to shutter their doors in compliance with distancing orders meant to control the spread of the disease, Golden Matrix experienced growth. It’s well recognized that in times of turmoil, so-called “sin stocks” generally outperform because people generally won’t eliminate vices like gambling, alcohol, and tobacco from their lives. When it comes to gambling, consumers had to become familiar with the digital world with physical businesses closed for months on end. Unfortunately for some operators, business was lost because they simply weren’t prepared for the online demand. As Golden Matrix CEO Brian Goodman recently said in a Benzinga interview, “If you don’t have an online presence in today’s world, then you’re a dinosaur.” Thankfully for Golden Matrix, there were still plenty of dinosaurs roaming around in dire need for customizable mobile and desktop gambling technology. Exclusively operating a business-to-business (“B2B”) model since inception in 2008, Golden Matrix expanded into the business-to-consumer (“B2C”) market late last year with the acquisition of an 80% stake in United Kingdom-based RKingsCompetitions Ltd. RKings runs online raffle competitions throughout England and Ireland. With RKings folded into the mix, Golden Matrix has continued to build momentum during its fiscal year 2022. In the nine months ended July 31, 2022, revenue jumped to $26.46 million, a gain of 237% from $7.84 million in the year earlier period. Net income for the nine months was $1.56 million, up 135% year-over-year, even with added expenses related to the RKings acquisition. Golden Matrix has now been profitable for four consecutive years on a calendar basis. Going forward, the company is preparing to make its initial foray into the Latin American markets in 2023. After acquiring RKings, GMGI secured a gaming license in Mexico and assembled an in-house team fluent in Spanish and Portuguese to overcome any language barriers as it launches its online B2C casino business. With only a few weeks to go in the fiscal year, Golden Matrix will look to run its streak to 17 profitable quarters and 4 straight complete fiscal years. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

Canada’s leading Cannabis Conference and Trade Show, Lift&Co. Expo, invites all members of the cannabis industry and community to its upcoming Vancouver event taking place January 12-14, 2023, at the Vancouver Convention Centre. For a limited time, Lift&Co. Expo is releasing a limited number of discounted Lift Cannabis Business Conference (“LCBC”) + Expo All-Access presale tickets for $350 (regularly priced at $599). Starting on day one, the Lift Cannabis Business Conference will tackle timely industry topics such as cannabis blockchain, brand and retailer relations, and cannabis real estate investing. It will also explore laws and regulations that need to change in time with the government review at the end of 2022. New voices anticipated at the conference include Dr. Everton Flemmings, Founder & President of iValley Nutraceuticals; and David Goldstein, CEO of Stoke Inventory Partners. Also sharing their invaluable knowledge and insight are leading industry experts such as Jaclynn Pehota, Executive Director of The Retail Cannabis Council of Canada and George Smitherman of The Cannabis Council of Canada. Continuing on days two and three, the Expo will showcase 200+ exhibiting companies from across the full “seed to sale” spectrum in a high-energy setting. In addition, the event is legendary for its networking opportunities, offering attendees the chance to establish ties among businesses, traders, vendors, cultivators, and more. Indeed, ever-growing audiences join in every year to be a part of this larger-than-life event that sees packed houses and a well-planned agenda. The experience at the Lift&Co. Expo is unmatched, with scintillating music, unending conversations and the free exchange of ideas. Plush amenities include multiple lounge areas, interactive booth set-ups and premium partner hotels, just to name a few. The presale LCBC ticket and all-access pass includes:

• Exclusive access to Lift Cannabis Business Conference
• Complimentary morning and afternoon breaks and lunch
• Industry networking reception
• Full access to the Exhibit Hall showcase of more than 200+ companies
• Full access to Exhibit Hall programming, including speakers, panels and demonstrations
• Full access to the new Brand Discovery Pavilion and Retailer Zone
• Exclusive ticket to the Lift&Co. Expo After Party

Attendees can visit the Lift&Co. Expo website to secure their presale ticket, for a limited time only. To learn more, please visit https://liftexpo.ca/lift-co-expo-vancouver-2023/

• Three out of four adults living with hypertension do not have the condition under control, putting them at risk for other serious complications
• Lexaria’s proposed therapy for hypertension is the highly efficient DehydraTECH-CBD, which has presented with no serious adverse side effects in test participants
• Dominated by the North American market, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026

In the United States, over 121.5 million adults are affected by high blood pressure – with statistics stacked against people of color, those with a family history of high blood pressure, heart disease, stroke, or kidney disease, and women who experienced blood pressure problems during pregnancy. According to the American Heart Association, high blood pressure is defined as a systolic pressure of 130 or higher and a diastolic pressure of 80 or higher that stays high over a period of time (https://ibn.fm/hsXw6). For some, managing high blood pressure is as simple as changing daily habits or being proactive about monitoring it if there is a history or predisposition to the disease. Early detection can protect the brain, reducing the risk of stroke, dementia, and other vascular diseases that affect the brain. Although high blood pressure is not the only risk factor associated, being conscious of it can help preserve the brain’s blood vessels. Unfortunately, three out of four adults do not have their high blood pressure under control, creating an unmet need in the hypertension treatment market. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to address the unmet needs of adults with high blood pressure (hypertension). DehydraTECH is a patented drug delivery technology that improves the oral administration of Active Pharmaceutical Ingredients (“APIs”). The benefits of using DehydraTECH-enabled APIs include the following:

• Improvement of onset speed – effects of the drug are felt in minutes
• Masked unwanted tastes – eliminates the need for sugar-filled edibles
• Increased bioavailability – the technology is more effective at delivering the drug into the bloodstream
• Increased brain absorption – testing has seen up to 27x improvement in the amount of the drug crossing the blood-brain barrier
• Reduction in drug administration costs – the higher ratio of the drug being delivered is expected to lower the overall costs of administration

Lexaria’s initial focus on hypertension has been its DehydraTECH-CBD, which is currently in the IND enabling studies phase and is actively developing lead product pipeline candidates. The advanced hypertension program has delivered positive results with no serious adverse effects, with the most recent being completed in 2021, with 16 participants exhibiting a reduction of attenuated pulmonary artery systolic pressure of approximately 5 mmHg, or 41% overall, in male participants. The company’s corporate presentation lists all of the results – from 2018-2021 (https://ibn.fm/X4psb). Results are pending from Lexaria’s largest ever human clinical trial, where dosing completed in July. According to Allied Market Research, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026, growing at a CAGR of 3.1% from 2019 to 2026. North America dominates the majority of the drug market. The market’s growth is expected due to the prevalence of hypertension across the globe and the interest in maintaining healthier lifestyles in the wake of the COVID-19 pandemic (https://ibn.fm/W8mNR). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

The EV Charging Infrastructure Summit is being held on October 18-19, 2022 as a live streaming event. CEOs, Directors, company heads, executives, professionals, and stakeholders of vehicle, electrical, transport and allied industries, are invited to attend this important event. The agenda of the event is to discuss the key issues that impact America’s critical EV infrastructure. It is estimated that by 2030, there will be more than 22 million EVs on U.S. roads. This raises the requirement for fast charging ports to more than 100,000, which is 10X times the increase over present numbers. The continued development of EV charging ports is essential for the growth and adoption of Electric Vehicles into urban infrastructure. At the EV Charging Infrastructure Conference, industry experts and veterans join hands to gather on this platform and cover significant issues addressing EV charging Infrastructure. Get deep insights into every detail of this industry, from scaling, operations, supply chain, grid strategy, and skills required to boost the growth of EV charging. Participants can avail this immense educational opportunity to understand the future of clean energy, the cutting-edge technology involved, and learn ways to leverage capital assets. Delve into the unique conference experience offering innovative ideas and untapped knowledge that will assist companies in preparing and expanding their EV businesses. Participate in the panel discussions, case studies, and keynote speeches by dignitaries attending the conference. They will impart their industry experience as well as share knowledge and skills needed to harness the power of EV business and technology. Budding businesses in the EV spectrum will showcase their products and services for profitable investment opportunities. Reasons to attend:

• Learn and access the latest technologies and skills for the development and installation of the EV charging infrastructure
• Understand how the EV charging infrastructure can prove lucrative for organizations
• Interact and network with the200+ EV charging companies and professionals to learn how to improvise their infrastructure and strategies
• Learn about the challenges and experiences of EV charging site hosts, municipalities and firms

The conference will feature engaging sessions from various technologies, including energy, battery, charging, transport, and load management, that support the framework for commercial and urban mobility. Attendees will learn the robust strategies to optimize EV Load management. Interact through 15-minute video chats and directly interact with experts in the EV charging domain. To learn more, please visit https://ibn.fm/edWja.